AcelRx reports Q3 net loss of $6.9M, DSUVIA sales up 217% YoY to $0.5M

TALPHERA, INC.

2022-Q3 EPS reported $7.46 revenue$1,519,000

DSUVIA net sales $0.5M in Q3 2022, up 217% vs Q3 2021; units sold 1,032 vs 371.
Net loss $6.9M ($0.94 per share) vs $8.4M ($1.40) in Q3 2021; cash $20.9M.
Combined R&D and SG&A expenses fell to $6.6M from $10.1M on cost reductions.
Niyad development batch produced; potential EUA submission targeted for H1 2023.
Ephedrine pre-filled syringe NDA submission expected by year-end; DSUVIA strategic partner by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TALPHERA, INC. reported the third quarter of 2022 results: revenue $0.5 million, net income $6.9 million, EPS $0.94 per basic and diluted share.

Period: the third quarter of 2022
Revenue: $0.5 million
Net income: $6.9 million
EPS: $0.94 per basic and diluted share
Result: reported results

Exact text from the filing

● Third quarter 2022 DSUVIA net sales were $0.5 million, a 217% increase over 2021; year-to-date September 30, 2022 DSUVIA net sales were $1.5 million, representing a 51% increase over the same period in 2021. Total DSUVIA units sold in the third quarter of 2022 were 1,032 compared to 371 units in 2021. Total net revenues in the third quarter 2022 of $0.5 million declined $1.4 million compared to the same period in 2021 due to the recognition of $1.7 million in revenues in the third quarter of 2021 attributed to an upfront payment received related to our DZUVEO European licensing agreement. ● Combined R&D and SG&A expenses for the third quarter of 2022 totaled $6.6 million compared to $10.1 million for the third quarter of 2021. Excluding non-cash depreciation and stock-based compensation expense, these amounts were $5.7 million for the third quarter of 2022, compared to $8.6 million for the third quarter of 2021. The decrease in combined R&D and SG&A expenses in the third quarter of 2

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-027267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.